top of page


News //

Aether secures $1.7 Mn Fast-track grant

May 15, 2018

Aether Therapeutics, an Austin-based, innovative new biotech company developing a first-in-class preventative treatment for Neonatal Abstinence Syndrome, was awarded a Fast-Track Small Business Innovation Research (SBIR) Grant from the National Institute of Drug Abuse (NIDA). 

Aether Completes license with The Ohio State University

July 1, 2018

Aether Therapeutics announced today it's finalized the negotiations with The Ohio State University as part of its effort to secure the exclusive license for the use of 6BN for the treatment and avoidance of neonatal abstinence syndrome.

Aether Collaborates with Ohio Neonatal Consortium

July 22, 2018

Aether Therapeutics has partnered with Ohio's three Neonatal Research Centers as part of a collaborative clinical developmental effort, which will ensure the ability to recruit patients under excellent resource conditions including facilities, key subject matter experts, clinical protocols, and standardized treatment protocols developed by the OPQC.  Ohio has been one of the hardest hit states by the opioid epidemic, but has also been a leading state in the development of standard of care for treating babies exposed to opioids in utero.

bottom of page